Non-alcoholic fatty liver disease （NAFLD） is an epidemic metabolic condition driven by an underlying lipid homeostasis disorder. The lipid droplet （LD）, the main organelle involved in neutral lipid storage and hyd...Non-alcoholic fatty liver disease （NAFLD） is an epidemic metabolic condition driven by an underlying lipid homeostasis disorder. The lipid droplet （LD）, the main organelle involved in neutral lipid storage and hydrolysis, is a potential target for NAFLD therapeutic treat- ment. In this review, we summarize recent progress elucidating the connections between LD-associated proteins and NAFLD found by genome-wide association studies （GWAS）, genomic and proteomic studies. Finally, we discuss a possible mechanism by which the protein 17β-hydroxysteroid dehydrogenase 13 （17β- HSD13） may promote the development of NAFLD.展开更多
基金The authors thank Dr. John Zehmer for his critical reading and useful suggestions. This work was supported by the National Natural Science Foundation of China （Grant No. 31100854 and U 1402225）, the Ministry of Science and Technology of China （Grant No. 2016YFA0500100）, the Importation and Development of High-Caliber Talents Project of Beijing Municipal Institutions （CIT＆TCD201504086）.
文摘Non-alcoholic fatty liver disease （NAFLD） is an epidemic metabolic condition driven by an underlying lipid homeostasis disorder. The lipid droplet （LD）, the main organelle involved in neutral lipid storage and hydrolysis, is a potential target for NAFLD therapeutic treat- ment. In this review, we summarize recent progress elucidating the connections between LD-associated proteins and NAFLD found by genome-wide association studies （GWAS）, genomic and proteomic studies. Finally, we discuss a possible mechanism by which the protein 17β-hydroxysteroid dehydrogenase 13 （17β- HSD13） may promote the development of NAFLD.
